Loading...
•
Jun 30, 2025
Integra LifeSciences Q2 2025 Earnings Report
Integra LifeSciences' second quarter 2025 financial results were reported, with revenues exceeding guidance and adjusted EPS at the top end of the range, despite a significant goodwill impairment charge.
Key Takeaways
Integra LifeSciences reported second-quarter 2025 revenues of $415.6 million, a slight decrease of 0.6% year-over-year. GAAP EPS was significantly impacted by a $511 million goodwill impairment charge, resulting in a net loss of $(484.1) million and diluted EPS of $(6.31). However, adjusted EPS was $0.45, meeting the top end of their guidance. The company highlighted strong demand for neurosurgery and tissue technology products and progress on their Compliance Master Plan.
Second quarter revenues reached $415.6 million, exceeding guidance, though representing a 0.6% decrease on a reported basis year-over-year.
GAAP diluted EPS was $(6.31), primarily due to a $511 million goodwill impairment charge, while adjusted diluted EPS was $0.45, at the high end of the guidance range.
The company reported a GAAP net loss of $(484.1) million, a significant decline from a net loss of $(12.4) million in the prior year, largely due to the impairment charge.
Integra LifeSciences generated $8.9 million in cash flow from operations during the quarter, and maintained total liquidity of approximately $1.14 billion.
Revenue by Segment
Forward Guidance
For Q3 2025, Integra LifeSciences expects revenues between $410 million and $420 million, with adjusted EPS in the range of $0.40 to $0.45. The full-year 2025 revenue guidance has been updated to $1.655 billion to $1.680 billion, and adjusted EPS guidance is reaffirmed at $2.19 to $2.29 per share.
Positive Outlook
- Third-quarter 2025 reported revenue growth is projected between 7.7% and 10.3%.
- Third-quarter 2025 organic revenue growth is expected to be between 7.3% and 9.9%.
- Full-year 2025 revenue guidance range has been updated to reflect increased visibility.
- Full-year 2025 adjusted EPS guidance of $2.19 to $2.29 per share has been reaffirmed.
- The company anticipates continued strong demand for its differentiated portfolio.
Challenges Ahead
- The company did not provide a reconciliation to GAAP EPS for forward-looking guidance due to the high variability and uncertainty of certain GAAP expense items.
- The financial impact and timing of divestitures, acquisitions, integrations, and structural optimization are uncertain.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...